SCHEMBL4629735

SCHEMBL4629735

CC1CCCCN1c1ccccc1CN

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NCF1 P14598 1/20 0.47
▸ SMARCA2 P51531 6/20 0.45
▸ SMARCA4 P51532 6/20 0.45
▸ PBRM1 Q86U86 6/20 0.45
▸ NR1I2 O75469 5/20 0.45
▸ NR1H3 Q13133 2/20 0.45
▸ NR1H2 P55055 2/20 0.45
▸ TPH1 P17752 1/20 0.44
▸ GFER P55789 1/20 0.44
▸ BCHE P06276 1/20 0.43
▸ ACHE P22303 1/20 0.43
▸ AR P10275 2/20 0.43
▸ LMNA P02545 1/20 0.42
▸ HTT P42858 1/20 0.42
▸ SMN1; SMN2 Q16637 1/20 0.42
▸ NCOA3 Q9Y6Q9 1/20 0.42
▸ MAOA P21397 1/20 0.39
▸ MAOB P27338 1/20 0.39
▸ CSF1R P07333 1/20 0.39
▸ CHRM4 P08173 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16814949 0.79 NCF1 (0.46) NCF1GFERACHECHRM4HRH3
SCHEMBL29512584 0.79 PBRM1 (0.54) SMARCA2SMARCA4PBRM1NR1I2NR1H3
SCHEMBL23043568 0.79 PBRM1 (0.54) SMARCA2SMARCA4PBRM1NR1I2NR1H3
SCHEMBL2107135 0.76 BCHE (0.47) SMARCA2SMARCA4PBRM1NR1I2NR1H3
SCHEMBL5153091 0.75 HRH3 (0.45) SMARCA2SMARCA4PBRM1NR1I2NR1H3
SCHEMBL16792864 0.75 MAPT (0.43) SMARCA2SMARCA4PBRM1NR1I2NR1H3
SCHEMBL16814971 0.74 MAPT (0.42) SMARCA2SMARCA4PBRM1NR1I2NR1H3
SCHEMBL9424277 0.73 MEN1 (0.54) SMARCA2SMARCA4PBRM1NR1I2NR1H3
SCHEMBL26288710 0.73 KMT2A (0.51) BCHEACHEARLMNACHRM4
SCHEMBL26288600 0.73 KMT2A (0.51) BCHEACHEARLMNACHRM4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7456195-B2 Phenylglycinamide and pyridylglycinamide derivatives useful as anticoagulants BRISTOL-MYERS SQUIBB COMPANY (US) 2008-11-25 — — US disclosed
EP-1910298-A2 PHENYLGLYCINAMIDE AND PYRIDYLGLYCINAMIDE DERIVATIVES USEFUL AS ANTICOAGULANTS Brystol-Myers Squibb Company (US) 2008-04-16 — — EP disclosed
WO-2007002313-A2 PHENYLGLYCINAMIDE AND PYRIDYLGLYCINAMIDE DERIVATIVES USEFUL AS ANTICOAGULANTS BRISTOL-MYERS SQUIBB COMPANY (US) 2007-01-04 — — WO disclosed
US-20070003539-A1 Phenylglycinamide and pyridylglycinamide derivatives useful as anticoagulants BRISTOL-MYERS SQUIBB COMPANY (US) 2007-01-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070003539-A1 Phenylglycinamide and pyridylglycinamide derivatives useful as anticoagulants F12, F11, F7 NCF1 4468/4885SMARCA2 3622/4885SMARCA4 3855/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback